NovaDel Pharma Inc. (AMEX:NVD) announced that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715 entitled “Buccal, Polar and Non-Polar Spray containing Zolpidem” that covers a method of treating insomnia by administering zolpidem to human beings utilizing NovaMist Oral Spray spray technology. NovaDel’s oral spray technology is focused for unmet medical needs for a broad array of existing and future pharmaceutical products. The Company’s most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system.

NovaDel Pharma is a leading specialty pharmaceutical company that is into the development of oral spray formulations for a broad range of marketed drugs. The Company offers conventional oral dosage forms that has the potential for faster absorption of drugs into the bloodstream that leads to quick therapeutic effects and reduces first pass

Entest Biomedical Inc (OTC:ENTB) announced that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease also known as COPD, which is currently under development, can lead to substantial revenue opportunities in the near future. Entest Biomedical’s CEO and Chairman, David Koos stated that the current treatment for COPD is aimed at improving the quality of life of the patient and not curing the illness. Hence, Entest is working hard to reverse the damage from COPD.

Entest Biomedical Inc is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. Currently, the Company is into the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), testing procedures for diabetes, immuno-therapies for cancer, stem cell research applications for other illnesses and diabetes. The Company also is involved with medical device development (including stem cell extraction instrumentation). Entest is also seeking grant funding in excess of $3 million to support its

Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year. Both the companies had entered the research and license agreement in December 2006 with Wyeth provided for the initial three years research term. Under the extended collaboration agreement, Ligand Pharmaceuticals will receive US$3.1 million in research payments to continue the drug discovery and optimization of their lead candidate. Under the original agreement, Ligand Pharmaceutical was entitled to receive up to US$175 million as milestone payments for the successful development and commercialization of multiple products.

Ligand Pharmaceuticals is one of the growing companies that is into the discovery and development of new drugs that addresses critical unmet medical needs of patients with muscle wasting, hormone related diseases, osteoporosis, anemia, asthma and rheumatoid arthritis. Ligand’s drug discovery and development programs are based on advanced cell-based assays, gene expression tools and one of

Put These Two Promising Biotech Stocks on Your Watch List

by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132

All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved.

After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide.

But Provenge takes a novel approach to treatment. The drug is the first active immunotherapy to improve survival by training a patient’s immune system to attack the cancer. And since it uses the body’s natural defenses, patients only report flu-like symptoms instead of the nasty side effects associated with chemotherapy.

This

Pro-Pharmaceuticals, Inc. (OTC:PRWP) has announced that they have closed a US$310,000 tranche of a private placement for up to US$6.0 million with 10X Fund, L.P. which is purchasing their unregistered Series B convertible preferred stocks and warrants. This tranche brings the total raised to date from the 10X Fund to approximately US$4.1 million. Pro-Pharmaceuticals is one of the leading companies that is engaged in the discovery, development and commercialization of carbohydrate therapeutics for the advanced treatment of patients suffering from cancer and fibrosis. Other products that are in the pipeline focus more on decreasing the toxicity of chemotherapy drugs.

The Company has decided to use the proceeds from the financing of partnership development and approval in countries with their own approval process as well as for general corporate purposes. At the closing of the tranche, the Company issued and sold

MabCure N.V., a subsidiary of MabCure Inc (OTC:MBCI) today announced that they have signed a research agreement with AZ Sint Lucas Hospital in Belgium to conduct preclinical research on its monoclonal antibodies against different cancers. Currently, the company’s monoclonal antibodies for the diagnosis of ovarian cancer, prostrate cancer, and colorectal cancer are aimed at diagnosing early stage disease in physiological samples such as urine and serum. The Sint Lucas General Hospital in Bruges is an independent hospital with emphasis on advanced patient care, active clinical research and participation in multi-center clinical trials.

MabCure Inc is a leading biotechnology company which is working hard to treat cancer. The Company has proprietary technology for the creation of unique and highly specific monoclonal antibodies also known as MAbs, which will be developed and used as diagnostic tools, imaging agents, and drugs for the

Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases. The Company further said that the oral immune regulation platform is a bright area of therapeutic promise. Currently, the Company’s therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicine for uveitis and Crohn’s disease and is conducting pre-clinical research on several candidate compounds that are aimed at producing new mineral and organic bone, including therapies for osteoporosis and fractures and other applications.

The Company announced that their therapeutics subsidiary has long viewed oral immune regulation as a promising platform and that they continue to pursue this platform through studies that involve treatment candidates of unmet medical needs. Enzo Biochem’s Vice President for Corporate Development, David Goldberg, mentioned

Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (PINK: NRIFF), a Canadian drug development company, both have an action date of today 11/4/2009 from the Food and Drug Administration (FDA) under the Prescription Drug User Fee Act (PDUFA) for their drug Pennsaid (diclofenac sodium) topical solution 1.5%.

Nuvo provided the FDA with supplemental information back in August that caused the FDA to extent its action date by three months to today.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in

Omnicare, Inc. (NYSE:OCR) have announced today that they have gone ahead and finalized the previously disclosed agreement for a voluntary civil settlement with the US Attorney’s Office, District of Massachusetts, the Department of Justice and Health and Human Services, as well as various of the states in which the Company runs its business. The civil settlement is related to the previously disclosed investigation with respect to qui tam complaints filed against Omnicare. The Company has agreed to cooperate fully with the reviews done by several departments of these matters and is pleased to have reached a resolution.

Omnicare, Inc is a Fortune 500 company based in Kentucky and one of the leading providers of pharmaceutical care for the elderly. The Company is into providing long term care facilities, chronic care and other settings that comprises of around 1.4 million beds

Universal Detection Technology (OTC:UNDT) has announced that they are expanding their product catalogue which will now include a consumer ready kit for the detection of black mold. The Company has been a developer of early warning monitoring technologies that protect people from bioterrorism and other infectious health hazards and threats. UNDT said that the lethal toxin can be found in areas of high humidity or flood damaged homes and cause serious problems and other health complications which can spread. According to the research and studies done by Mayo clinic nearly all sinus infection are results of mold and currently there are around 37 million Americans suffering from chronic sinus infections.

 Universal Detection Technology is one of the leading developers for monitoring technologies that includes bioterrorism detection devices. The Company on its own and with it development partners has the capability to